What cough suppressants are recommended for a healthy adult with a non‑productive cough?

Cough Suppressants for Healthy Adults with Non-Productive Cough

For a healthy adult with non-productive cough, the evidence does not support routine use of cough suppressants, as most agents show limited efficacy in this population.

Key Recommendations Based on Underlying Cause

The most critical factor is identifying whether the cough is due to an upper respiratory infection (URI/common cold) versus chronic bronchitis, as treatment efficacy differs dramatically between these conditions 1.

For Non-Productive Cough Due to URI/Common Cold

Central cough suppressants (codeine, dextromethorphan) are NOT recommended for cough due to URI, as they have limited efficacy for symptomatic relief despite widespread use 1. This is a Grade D recommendation with good evidence showing no benefit 1.

• Peripheral cough suppressants also have limited efficacy and are not recommended for URI-related cough 1
• Over-the-counter combination cold medications (except older antihistamine-decongestant combinations) are not recommended until proven effective in randomized controlled trials 1
• Zinc preparations are not recommended for acute cough due to common cold 1

For Non-Productive Cough Due to Chronic Bronchitis

If the patient has chronic bronchitis rather than simple URI, treatment options expand significantly:

• Central cough suppressants (codeine and dextromethorphan) are recommended for short-term symptomatic relief in chronic bronchitis 1. This is a Grade B recommendation with fair evidence showing intermediate benefit 1
• Peripheral cough suppressants (levodropropizine, moguisteine) are recommended for short-term symptomatic relief in chronic or acute bronchitis 1. This carries a Grade A recommendation with good evidence showing substantial benefit 1
• Ipratropium bromide (inhaled anticholinergic) is the only recommended inhaled agent for cough suppression in chronic bronchitis 1. This is a Grade A recommendation with substantial benefit 1

Evidence Quality and Comparative Effectiveness

Recent research supports levodropropizine as superior to traditional central antitussives. A 2015 meta-analysis of 1,178 patients demonstrated statistically significant better overall efficacy of levodropropizine versus central antitussive drugs (codeine, cloperastine, dextromethorphan) in reducing cough intensity, frequency, and nocturnal awakenings (p = 0.0015) 2.

A head-to-head comparison showed levodropropizine (60 mg three times daily) reduced cough intensity earlier than dextromethorphan (15 mg three times daily) and produced significantly fewer adverse events (3.6% vs 12.1%, p < 0.05), with half the somnolence rate (4.6% vs 10.4%) 3.

Important Caveats

Agents that do NOT work and should be avoided:

• Guaifenesin and other mucolytics are not recommended for cough suppression in chronic bronchitis 1
• Albuterol is not recommended for acute or chronic cough not due to asthma 1
• Drugs affecting the efferent limb of the cough reflex are not recommended 1

Clinical Approach

For a truly healthy adult with isolated non-productive cough (no chronic bronchitis):

1. First, determine the cause: URI versus other etiologies 1
2. If URI-related: Avoid cough suppressants as they lack efficacy; focus on supportive care and time 1
3. If chronic bronchitis is present: Consider ipratropium bromide as first-line, or peripheral suppressants (levodropropizine/moguisteine if available), or central suppressants (codeine/dextromethorphan) for short-term use 1
4. Duration: Limit suppressant use to short-term symptomatic relief only 1

The ACCP guidelines emphasize that "relatively few drugs are effective for the nonspecific suppression of cough" and that "use of suppressants should be guided by the physician's specific knowledge of the disorder that is eliciting cough" 1.